Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aegerion Pharmaceuticals Inc.

Division of Novelion Therapeutics Inc.
www.aegerion.com

Latest From Aegerion Pharmaceuticals Inc.

Novo's Victoza REMS Settlement Opens Another Legal Door For Off-Label Promotion Cases

US government alleged sales reps gave information to physicians to create a false or misleading impression that Victoza's boxed warning and REMS messages about medullary thyroid cancer were 'erroneous, irrelevant or unimportant.' Novo's $59m settlement includes resolution of whistleblower lawsuits alleging off-label marketing.

Advertising, Marketing & Sales Legal Issues

Deals Shaping the Medical Industry, January 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Deals BioPharmaceutical

Deal Watch: Focus Placed On Psoriasis With Recent Purdue, Sienna Deals

Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.

Deals M & A

Execs On The Move, November 2016

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novelion Therapeutics Inc.
  • Senior Management
  • Mary Szela, CEO
    Gregory D Perry, CFO
    Remi A Menes, Chief Commercial Officer
  • Contact Info
  • Aegerion Pharmaceuticals Inc.
    Phone: (855) 305-2347
    One Main St., Ste. 800
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register